The open-label, dose escalation study is designed to define the recommended dose of XmAb2513 for subsequent trials, to determine its safety and tolerability, characterize pharmacokinetics and immunogenicity, and to evaluate its antitumor activity in patients with Hodgkin lymphoma (HL) and anaplastic large cell lymphoma (ALCL) who have received two or more prior therapeutic treatments. XmAb2513 is a humanized monoclonal antibody that targets the antigen CD30. It is engineered to contain an XmAb Fc domain using Xencor’s Protein Design Automation platform technology to greatly increase its cytotoxic potency.
Jeffrey Bloss, chief medical officer of Xencor, said: “This is a very promising compound within our pipeline, and we believe it has multiple applications in the treatment of lymphoma and other cancers.”